Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONCT 808

Next Previous
Drug Profile

ONCT 808

Alternative Names: ONCT-808; ROR1 CAR-T cell therapy; ROR1 targeted CAR-T therapy - Oncternal Therapeutics; ROR1-CAR-T

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Oncternal Therapeutics, Inc.
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued B-cell lymphoma; Solid tumours

Most Recent Events

  • 07 Dec 2024 Efficacy, pharmacokinetics and adverse event data from a phase I/II trial in B-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 18 Sep 2024 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
  • 12 Sep 2024 Oncternal Therapeutics terminates a phase I/II trial in B-cell lymphoma (Second-line therapy or greater, late-stage disease) in USA (IV) based on the available clinical data and capital requirements for continued development (NCT05588440)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top